Trending Videos
Shorts

0:40
How unequal PSMA-PET access may affect prostate cancer care
3 hours ago
by
Juan Gómez Rivas, MD, FEBU, PhD

0:33
What a positive NeoBLAST trial would mean for MIBC care
3 days ago
by
Marie-Pier St-Laurent, MD, FRCSC

0:43
Why independent urology practices face growing pressure
4 days ago
by
Celeste Kirschner, CAE, MHSA

1:33
The long-term cost question behind OAB drug selection
5 days ago
by
Anjali Kapur, MD

0:51
How to spot patients chasing a product, not a diagnosis
6 days ago
by
Jean Cunningham, PharmD, BCPS

0:24
How NeoBLAST defines and confirms complete response
7 days ago
by
Marie-Pier St-Laurent, MD, FRCSC

1:09
Considering the practical benefits of intraoperative chemotherapy at nephroureterectomy
10 days ago
by
Adam B. Weiner, MD(+1 more)

0:22
What the evidence says on penile cancer margin management
11 days ago
by
Luis G. Medina, MD

0:21
4 steps to implementing a rapid access model for elevated PSA
12 days ago
by
Zach Feuer, MD

0:30
The ambition behind the first MIBC surveillance RCT
13 days ago
by
Marie-Pier St-Laurent, MD, FRCSC
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
3
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
4
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
5































